Consistently, a selective inhibitor of TLR4 signaling, C34, limits the capability of MSCs to sustain MM cell proliferation showing also additive effects with the antimyeloma drug lenalidomide. The gene discussed is TLR4; the disease is Miyoshi myopathy.